Loading stock…

ADMA Biologics, Inc. (ADMA) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

ADMA Biologics, Inc.

ADMAMarket cap $2.27BPrice $10.1

Country🇺🇸United States

SectorHealthcare

IndustryBiotechnology

Manufactures plasma-derived biologics that treat immune deficiencies in patients too vulnerable to fight infections alone. Its FDA-approved antibody therapies come from human plasma, a supply chain so tight that ADMA controls its own collection centers to secure it.

In Bastion Portfolios?

52W Return-29%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+49%10

Revenue Forecast

Rev CAGR (1y)+4%4

Rev CAGR (3y)+11%7

Rev CAGR (5y)+12%8

Earnings Forecast

EPS Growth Y+1+30%9

EPS Growth Y+2+27%8

EPS Growth Y+3+26%8

Quality

Margins

EBIT Margin42%10

Net Income Margin33%9

Free Cash Flow Margin23%8

Debt

Net Debt/EBITDA0.37

Efficiency

ROE42%10

ROA27%10

Earnings Stability33

GEAR+VERY STRONG92

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)127

P/E Ratio (Forward 3y)89

P/BV5.63

EV Multiples

EV/EBITDA Fwd87

EV/EBIT Fwd109

Yield

Free Cash Flow Yield5.1%6

Dividend Yieldna–

Momentum

Short term

1 month return+6%9

3 month return+11%9

YTD return-44%1

Mid term

Price vs 52wHigh50%1

1 year return-31%2

Long term

3 year return+203%9

5 year return+805%10

Risk Shield

Price Risk

Beta0.85

Volatility55%2

Free Cash Flow

Free Cash Flow Margin23%8

Free Cash Flow Yield5.1%6

Quality

ROCE40%10

Earnings Stability33

Net Debt/EBITDA0.37

02Growth

Is it actually growing, and how fast?

ADMAADMA Biologics

Revenue FY25$510M

GROWTH RATING↗

STRONG72 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+49%10

Revenue, next 1Y+4%4

Revenue, next 3Y, CAGR+11%7

Revenue, next 5Y, CAGR+12%8

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+30%9

EPS growth, FY27E+27%8

EPS growth, FY28E+26%8

GROWTH ASSESSMENT

STRENGTHS

It out-grows 72% of companies worldwide.

Revenue grew 49%/yr over the last 3 years, ahead of 90% of companies worldwide.10/10

The runway holds up: revenue is set to grow 12%/yr over five years.8/10

Earnings are set to grow faster than sales (EPS about 27%/yr vs revenue 11%/yr), so margins should widen.

WATCH

Revenue is set to grow 11%/yr over the next 3 years, a little ahead of the market.6/10

Revenue grew 49%/yr over the last 3 years; forecasts see it cooling to 11%/yr.

WEAKNESSES

None flagged.

BOTTOM LINE

Elite Compounder

A top-tier grower that is slowing. The one thing to watch: the pace is cooling.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

AVERAGE65 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+6%9

3-month return+11%9

YTD return-44%1

MID & LONG-TERM▾SCORE

% of 52-week high50%1

1-year return-31%2

3-year return+203%9

5-year return+805%10

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +203% over three years and +805% over five, ahead of 90% of the market.

Strong recent results. The stock is outperforming over the past month (+6%) and over three months (+11%).

WATCH

None flagged.

WEAKNESSES

It's down 31% over the past year, now 50% below its 52-week high. That is lagging the market.

The stock is underperforming so far this year (-44%).

BOTTOM LINE

Momentum Leader

Short- and long-term returns both rank among the best globally. The market is behind it — a core fit for momentum strategies. The one thing to watch: the one-year trend is weak.

04Value

Are you paying a fair price for it?

Stop guessing on ADMA Biologics, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

ADMAADMA Biologics

Revenue FY25$510M

GROWTH RATING↗

STRONG72 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+49%10

Revenue, next 1Y+4%4

Revenue, next 3Y, CAGR+11%7

Revenue, next 5Y, CAGR+12%8

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+30%9

EPS growth, FY27E+27%8

EPS growth, FY28E+26%8

GROWTH ASSESSMENT

STRENGTHS

It out-grows 72% of companies worldwide.

Revenue grew 49%/yr over the last 3 years, ahead of 90% of companies worldwide.10/10

The runway holds up: revenue is set to grow 12%/yr over five years.8/10

Earnings are set to grow faster than sales (EPS about 27%/yr vs revenue 11%/yr), so margins should widen.

WATCH

Revenue is set to grow 11%/yr over the next 3 years, a little ahead of the market.6/10

Revenue grew 49%/yr over the last 3 years; forecasts see it cooling to 11%/yr.

WEAKNESSES

None flagged.

BOTTOM LINE

Elite Compounder

A top-tier grower that is slowing. The one thing to watch: the pace is cooling.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

AVERAGE65 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+6%9

3-month return+11%9

YTD return-44%1

MID & LONG-TERM▾SCORE

% of 52-week high50%1

1-year return-31%2

3-year return+203%9

5-year return+805%10

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +203% over three years and +805% over five, ahead of 90% of the market.

Strong recent results. The stock is outperforming over the past month (+6%) and over three months (+11%).

WATCH

None flagged.

WEAKNESSES

It's down 31% over the past year, now 50% below its 52-week high. That is lagging the market.

The stock is underperforming so far this year (-44%).

BOTTOM LINE

Momentum Leader

Short- and long-term returns both rank among the best globally. The market is behind it — a core fit for momentum strategies. The one thing to watch: the one-year trend is weak.

04Value

Are you paying a fair price for it?

Stop guessing on ADMA Biologics, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community